Zenas BioPharma (NASDAQ:ZBIO) Shares Down 8.8% - What's Next?

Key Points

• Zenas BioPharma shares experienced an 8.8% decline during mid-day trading, closing at $15.33, with trading volume significantly lower than average.
• Analysts have mixed views, with Wedbush maintaining an "outperform" rating and a $35 target price, while HC Wainwright set a $30 target, indicating potential upside despite the recent stock decline.
• The company reported earnings of ($0.80) per share, exceeding expectations, with revenue of $10 million against forecasts of $5 million, highlighting a positive financial performance amid stock pressures.

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) fell 8.8% during trading on Tuesday . The company traded as low as $15.32 and last traded at $15.33. 80,218 shares were traded during trading, a decline of 56% from the average session volume of 183,143 shares. The stock had previously closed at $16.81.

Analyst Ratings Changes

A number of research firms have commented on ZBIO. Wedbush reaffirmed an "outperform" rating and set a $35.00 price objective on shares of Zenas BioPharma in a research note on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Zenas BioPharma in a research note on Friday, May 16th.

Zenas BioPharma Price Performance

The company has a 50-day moving average of $12.11. The company has a market capitalization of $611.97 million and a price-to-earnings ratio of -4.12.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.35. The company had revenue of $10.00 million during the quarter, compared to analysts' expectations of $5.00 million.

Institutional Trading of Zenas BioPharma

A number of hedge funds have recently made changes to their positions in ZBIO. New York State Common Retirement Fund purchased a new stake in shares of Zenas BioPharma in the first quarter worth approximately $49,000. Jefferies Financial Group Inc. acquired a new position in Zenas BioPharma in the first quarter worth approximately $348,000. Nuveen LLC bought a new position in Zenas BioPharma during the first quarter valued at approximately $250,000. PNC Financial Services Group Inc. raised its position in Zenas BioPharma by 41.2% during the second quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after acquiring an additional 2,679 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock valued at $3,621,000 after acquiring an additional 16,461 shares in the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.